文献速递帕金森病与运动障碍

新发帕金森病唾液生物标志物联合检测面板

A Combined Panel of Salivary Biomarkers in de novo Parkinson's Disease.
PubMed 文献 · Ann Neurol · 2023-01-02

该研究检测了80例新发帕金森病患者和62名健康受试者唾液中的总α-突触核蛋白、寡聚α-突触核蛋白、总tau、磷酸化tau、MAP-LC3β和TNFα,发现寡聚α-突触核蛋白、总tau、MAP-LC3β和TNFα在患者中显著升高,寡聚α-突触核蛋白和MAP-LC3β具有准确的诊断性能,总α-突触核蛋白与其他通路标志物联合可提高诊断准确性。

要点

  • 新发帕金森病患者唾液寡聚α-突触核蛋白、总tau、MAP-LC3β和TNFα水平显著高于健康受试者。
  • 唾液寡聚α-突触核蛋白和MAP-LC3β对区分新发帕金森病与健康受试者具有准确的诊断性能。
  • 总α-突触核蛋白与其他唾液生物标志物联合可提高诊断准确性。

核心结论

  • 研究提出了一种使用唾液(一种非侵入性生物流体)的新发帕金森病生物标志物面板,有助于理解帕金森病发病机制涉及的分子通路以及不同分子通路在决定临床帕金森病亚型中的相关性。

研究设计与样本

  • 研究纳入80例新发帕金森病患者和62名健康受试者,采用定量酶联免疫吸附分析检测唾液中的总α-突触核蛋白、寡聚α-突触核蛋白、总tau、磷酸化tau、微管相关蛋白轻链3β(MAP-LC3β)和肿瘤坏死因子α(TNFα)。

主要发现

  • 寡聚α-突触核蛋白、总tau、MAP-LC3β和TNFα水平在帕金森病患者中显著高于健康受试者,而总α-突触核蛋白和磷酸化tau未检测到显著差异。
  • 在帕金森病患者中,磷酸化tau与MAP-LC3β直接相关,而与TNFα呈负相关。
  • MAP-LC3β与非运动症状严重程度呈负相关。
  • 主成分分析显示,在新发帕金森病患者中分子参数与临床参数彼此独立。
  • 受试者工作特征曲线分析报告寡聚α-突触核蛋白和MAP-LC3β具有准确的诊断性能;总α-突触核蛋白与其他针对不同分子通路的唾液生物标志物联合时诊断准确性提高。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate molecular biomarkers of a-synuclein and tau aggregation, autophagy, and inflammation in the saliva of de novo Parkinson's disease (PD) patients in comparison to healthy subjects (HS), and to correlate molecular data with clinical features of PD patients, in order to establish whether abnormalities of these parameters are associated with specific clusters of de novo PD patients, and their potential diagnostic power in differentiating PD patients from HS. METHODS: We measured total and oligomeric a-synuclein, total-tau and phosphorylated-tau, microtubule-associated protein light chain 3 beta (MAP-LC3beta), and tumor necrosis factor alpha (TNFalpha) in the saliva of 80 de novo PD patients and 62 HS, using quantitative enzyme-linked immunosorbent Assay analysis. RESULTS: Oligomeric a-synuclein, total-tau, MAP-LC3beta, and TNFalpha levels resulted significantly higher in patients with respect to HS, while no significant differences were detected for total a-synuclein or phosphorylated-tau. Phosphorylated-tau directly correlated with MAP-LC3beta, whereas it inversely correlated with TNFalpha in PD patients. An inverse correlation was detected between MAP-LC3beta and non-motor symptoms severity. Principal Component Analysis showed that molecular and clinical parameters were independent of each other in de novo PD patients. Receiver operating characteristic curve analysis reported an accurate diagnostic performance of oligomeric a-synuclein and MAP-LC3beta. The diagnostic accuracy of total a-synuclein increased when it was combined with other salivary biomarkers targeting different molecular pathways. INTERPRETATION: Our study proposes a novel biomarker panel using saliva, a non-invasive biofluid, in de novo PD patients, with implications in understanding the molecular pathways involved in PD pathogenesis and the relevance of different molecular pathways in determining clinical PD subtypes. ANN NEUROL 2023;93:446-459.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. De Bartolo MI, Vivacqua G, Belvisi D, et al. A Combined Panel of Salivary Biomarkers in de novo Parkinson's Disease. Ann Neurol. 2023. PMID: 36385395. doi:10.1002/ana.26550

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。